The C-Type Lectin of the Aggrecan G3 Domain Activates Complement by Fürst, Camilla Melin et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The C-Type Lectin of the Aggrecan G3 Domain Activates Complement
Fürst, Camilla Melin; Mörgelin, Matthias; Vadstrup, Kasper; Heinegård, Dick; Aspberg,
Anders; Blom, Anna M.
Published in:
P L o S One
DOI:
10.1371/journal.pone.0061407
Publication date:
2013
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Fürst, C. M., Mörgelin, M., Vadstrup, K., Heinegård, D., Aspberg, A., & Blom, A. M. (2013). The C-Type Lectin of
the Aggrecan G3 Domain Activates Complement. P L o S One, 8(4), 1-11.
https://doi.org/10.1371/journal.pone.0061407
Download date: 02. Feb. 2020
The C-Type Lectin of the Aggrecan G3 Domain Activates
Complement
Camilla Melin Fu¨rst1, Matthias Mo¨rgelin2, Kasper Vadstrup3, Dick Heinega˚rd4, Anders Aspberg3,
Anna M. Blom1*
1 Department of Laboratory Medicine, Division of Medical Protein Chemistry, Lund University, Malmo¨, Sweden, 2 Department of Clinical Sciences, Division of Infection
Medicine, Lund University, Lund, Sweden, 3 Department of Biology, University of Copenhagen, Copenhagen, Denmark, 4 Department of Clinical Sciences, Section of
Rheumatology, Lund University, Lund, Sweden
Abstract
Excessive complement activation contributes to joint diseases such as rheumatoid arthritis and osteoarthritis during which
cartilage proteins are fragmented and released into the synovial fluid. Some of these proteins and fragments activate
complement, which may sustain inflammation. The G3 domain of large cartilage proteoglycan aggrecan interacts with other
extracellular matrix proteins, fibulins and tenascins, via its C-type lectin domain (CLD) and has important functions in matrix
organization. Fragments containing G3 domain are released during normal aggrecan turnover, but increasingly so in
disease. We now show that the aggrecan CLD part of the G3 domain activates the classical and to a lesser extent the
alternative pathway of complement, via binding of C1q and C3, respectively. The complement control protein (CCP) domain
adjacent to the CLD showed no effect on complement initiation. The binding of C1q to G3 depended on ionic interactions
and was decreased in D2267N mutant G3. However, the observed complement activation was attenuated due to binding of
complement inhibitor factor H to CLD and CCP domains. This was most apparent at the level of deposition of terminal
complement components. Taken together our observations indicate aggrecan CLD as one factor involved in the sustained
inflammation of the joint.
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Introduction
The complement system provides defense against foreign
pathogens but it also acts as a sensor of danger, aiding in the
removal of dying cells, immune-complexes and misfolded mole-
cules [1]. Misguided or excessive complement activation can on
the other hand contribute to a wide range of autoimmune
disorders and pathological inflammatory conditions such as
rheumatoid arthritis (RA) [2]. Complement activation products
can be found in synovial fluids of patients with active RA, and a
role for complement in RA is supported by the protective effect of
deficiencies of complement proteins in arthritis mouse models as
well as therapeutic effect upon complement inhibition in these
models [3].
Complement can be activated via three pathways; the classical
pathway is triggered by binding of various ligands such as clustered
IgG and IgM antibodies, C-reactive protein, DNA and lipopoly-
saccharide to the C1-complex consisting of the recognition protein
C1q, and two copies each of the proteolytic subunits C1s and C1r
[4]. The lectin pathway is initiated when mannose-binding lectin
(MBL) or ficolins bind to specific carbohydrate structures or
acetylated ligands [1] while the alternative pathway is commenced
by autoactivation of the unstable complement factor C3 and its
subsequent deposition on activating pathogen surfaces.
During pathologic cartilage destruction, cartilage proteins are
fragmented and released into the synovial fluid where they can
interact with complement. This has been proposed to contribute to
the local pro-inflammatory milieu in joints of patients suffering
from RA. C1q, the initiator of the classical pathway, binds to
decorin [5,6], biglycan [5], fibronectin [7], laminin [8], osteoad-
herin [6], fibromodulin [9], cartilage oligomeric matrix protein
(COMP) [10] and more weakly to lumican [6] and chondroad-
herin [6]. These interactions can result in inhibition of C1q
(decorin, biglycan, COMP) or in activation of the classical
pathway (fibromodulin, osteoadherin). Interestingly, those extra-
cellular matrix (ECM) molecules that activate C1q and the ensuing
complement cascade also bind complement inhibitors such as
factor H (FH) [6] and C4b-binding protein (C4BP) [11] in order to
limit inflammation. Furthermore, COMP, an established marker
of joint destruction, activates the alternative complement pathway
[10,12].
In the present study we investigated if aggrecan, which is the
major proteoglycan in the articular cartilage, may also engage in
interaction with complement. Aggrecan is expressed by chondro-
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cytes and it is heavily substituted with chondroitin sulphate (CS)
and keratan sulphate (KS) glycosaminoglycan chains, which retain
water, resulting in a pressure-resistant gel structure that provides
cartilage with its load-bearing properties. Aggrecan is also involved
in chondroskeletal morphogenesis during development [13]. The
glycosaminoglycan carrying region is flanked by globular domains
that mediate binding to other ECM molecules (Fig. 1A) [14]. The
N-terminal G1 domain interacts with link protein attached to
hyaluronan to organize aggrecan into larger units [15]. The C-
terminal G3 domain binds via the C-type lectin domain (CLD) to
the ECM proteins tenascins [16,17], fibulins [18,19] and fibrillin
[20]. The aggrecan G3 domain exists in different splice variants in
man, with optional epidermal growth factor-like domains (EGF)
and complement control protein (CCP) domain, which might fine-
tune interactions between CLD and its ligands [17]. G3 also has a
role in post-translational processing of the aggrecan core protein
and the subsequent secretion [21]. Mutations localized to the
CLD, V2303M and D2267N, are associated with familial
osteochondritis dissecans and spondyloepimetaphyseal dysplasia,
respectively [22,23]. In the former disorder parts of articular
cartilage and subchondral bone dislodge from the joint surface and
early onset osteoarthritis (OA). The latter disorder is characterized
by severe chondrodysplasia. The D2267N mutation introduces a
novel glycosylation site whereas the V2303M mutation likely leads
to conformational changes, both leading to disruption of the
interactions between CLD and its ECM ligands [22,23].
Aggrecan turnover is mediated by degradation by aggrecanases
and matrix metalloproteinases. The aggrecan monomer is cleaved
at several well-defined positions, and the C-terminal G3 and
variable parts of the CS-rich part of the molecule are progressively
liberated from cartilage into synovial fluid. The parts containing
the G1 domain are retained longer in the tissue due to binding to
hyaluronan [24,25]. The cleavages by aggrecanases are thought to
increase in joint diseases such as RA and OA. There are
indications that aggrecan might activate complement, shown by
the ability of full-length bovine aggrecan to induce the formation
of soluble C5b-9 (membrane attack complex, MAC) [26]. In the
present study we further dissected the complement activation
properties of intact aggrecan as well as of the globular domain G3.
Materials and Methods
Ethics Statement
Ethical approval for the study was obtained from the ethics
committee of Lund University (permit number 418/2008); written
consent was obtained from all participants (healthy volunteers)
who donated blood for preparation of serum. Fetal, calf and adult
bovine cartilage were obtained in the form of waste from a Scan
slaughterhouse in Ka¨vlinge, Ska˚ne, Sweden after obtaining
permission from this slaughterhouse to use these animal parts.
According to Swedish laws and regulations no ethical permit is
required for use of such waste in research.
Proteins and Sera
Recombinant proteins corresponding to splice variants of the
G3 domain of aggrecan were expressed from the pCEP4-BM40-
hisEK vector in embryonic kidney 293-EBNA cells and purified as
described previously [17,22]. The identity of the constructs was
confirmed by mass spectrometry and purity verified by electro-
phoresis (Fig. 1B). The constructs (LCt, Lt, Ct) contain an N-
terminal His-tag and combinations of a CLD (L), a CCP domain
(C) and a tail (t) (Fig. 1A). Two disease-associated mutants of the
LCt construct were created containing V2303M [22] and D2267N
[23] substitutions. The D2267N mutation was introduced through
QuickChange (Stratagene) site-directed mutagenesis using primers
59-TGG ATC GGC CTG AAC AAC CGT ACG ATC GAA
GGG GAC TTC CGC-39 and 59-GCG GAA GTC CCC TTC
GAT CGT ACG GTT GTT CAG GCC GAT CCA-39. The
V2303M mutation was introduced according to [22]. The mutant
proteins were expressed and purified as described for the wild type
constructs. Purity was verified by electrophoresis and the larger
Figure 1. Structure of aggrecan and localization of G3 domain fragments which were used in the study. A, schematic outline of human
aggrecan, including three globular domains (G1–G3), which is involved in numerous interactions with other ECM components. The carboxyl-terminal
globular G3 domain consists of one or two EGF-like domains, a C-type lectin domain (CLD) and a complement control protein (CCP) domain followed
by a short tail. In the current study we used three wild-type recombinant fragments of G3 domain: LCt, Lt and Ct and two mutants of LCt containing
D2267N or V2303M substitutions. B, the wild-type and mutated fragments of G3 domain were expressed in eukaryotic cells and separated by SDS/
PAGE followed by Coomassie Blue staining.
doi:10.1371/journal.pone.0061407.g001
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Figure 2. Lectin domain of aggrecan G3 module activates the
classical pathway. Aggregated IgG (positive control for classical
pathway), LCt, Lt, Ct and BSA (negative control) were coated onto
microtiter plates and increasing concentrations of normal human serum
(NHS) were added. Activation of the classical pathway was measured by
detecting deposited C1q (A), C4b (B), C3b (C) and C9 (D). The graphs
show the mean and standard deviation (SD) of three independent
experiments. Statistical significance of differences was calculated using
a two-way ANOVA with a Bonferroni posttest. * p,0.05, **p,0.01,
***p,0.001.).
doi:10.1371/journal.pone.0061407.g002
Figure 3. Lectin domain of aggrecan G3 domain activates
classical pathway due to binding of C1q. A, aggregated IgG
(positive control for classical pathway), mannan (positive control for
lectin pathway), LCt, Lt, Ct and BSA (negative control) were coated onto
microtiter plates and increasing concentrations of C1q-depleted human
serum were added. Activation of the classical pathway was measured
by detecting deposited C4b. The absorbance was normalized relative to
deposition on mannan from 10% C1q-depleted serum. B, aggregated
IgG, LCt, Lt, Ct and BSA were coated onto microtiter plates and
incubated with purified C1q, which was then detected with specific
antibodies. Aggregated IgG, LCt, Lt, Ct and BSA were coated onto
microtiter plates and incubated with purified C1q in a buffer
supplemented with increasing NaCl concentrations (C) or EDTA (D).
The graphs show the mean and SD of three independent experiments.
Statistical significance of differences was calculated using two-way
ANOVA with Bonferroni posttest (B, D). (*p,0.05, **p,0.01,
***p,0.001.).
doi:10.1371/journal.pone.0061407.g003
Aggrecan Activates Complement
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mass of D2267N compared to wild type is due to a glycosylation of
the substituted asparagine residue (Fig. 1B).
Intact aggrecan was extracted with 4 M guanidine-HCl from
fetal, calf and adult bovine articular cartilage, and purified by
CsCl-density gradient centrifugation, as described in [27].
Aggrecan used for electron microscopy was extracted and purified
from bovine nasal cartilage using the same protocol.
Normal human serum (NHS) was prepared from freshly drawn
blood, which was allowed to clot for 30 min at RT and 1 h on ice.
Each incubation step was followed by centrifugation. The serum
fractions were pooled and stored in aliquots at 280uC. To prepare
heat-inactivated serum (hi-NHS), NHS was incubated at +56u for
60 min. C3, C3b and properdin were from Complement
Technology. C1q [28], C4BP [29] and FH [30] were purified
from plasma as described, with additional purification of FH.
Samples containing FH were applied to an MRCOX-24 affinity
column, unbound proteins were washed away with 1 M NaCl in
TBS and FH was eluted with 3 M MgCl2 (pH 7.0) followed by
immediate dialysis against TBS.
Deposition of Complement Proteins from Serum and
Depleted Sera
Microtiter plates (Maxisorp, Nunc) were coated with 5 mg/ml
LCt, V2303M LCt, D2267N LCt (untreated or deglycosylated by
N-glycosidase F (29 U/mg, O/N at 37C; Roche Applied Science),
Lt and Ct recombinant fragments of aggrecan G3 domain in
75 mM sodium carbonate buffer (pH 9.6), O/N at 4uC. Ligands
known to activate the respective pathways of complement were
coated and used as positive controls; aggregated human IgG
(5 mg/ml, classical pathway; Immuno), mannan (50 mg/ml, lectin
pathway; M-7504 Sigma), acetylated BSA (10 mg/ml, lectin
pathway; Applichem, acetylated as described in [31]) or zymosan
(30 mg/ml, alternative pathway; Z-4250, Sigma). BSA does not
activate human complement and 1% BSA (Applichem) in PBS was
used as negative control. Plates were blocked with 1% BSA in PBS
for 2 h at RT. Increasing amounts of NHS, C1q-depleted serum
(Quidel) or factor B (FB)-depleted serum (Complement Technol-
ogy) in 50 mM Hepes pH 7.35, 100 mM NaCl, 0.15 mM CaCl2,
1 mM MgCl2 (classical and lectin pathway) or Mg
++EGTA (2 mM
veronal buffer, pH 7.4, 60 mM NaCl, 120 mM glucose, 0.1%
gelatin, 10 mM EGTA, 7 mM MgCl2; alternative pathway) were
added. Deposited complement components were detected with
specific antibodies, after incubation at 37uC for 20 min for C3b
and C4b (A063 and Q0369, Dako) deposition, or 45 min for C1q
(A0136, Dako), C9 (A226, Complement Technologies), MBL
(HYB 131-10, Antibodyshop), ficolin 2 [32] and ficolin 3 [33]
(kindly provided by P. Garred, University of Copenhagen,
Copenhagen, Denmark) deposition. For alternative pathway
activation, the incubation was for 35 min. The secondary
antibodies were HRP-conjugated (Dako) and plates were devel-
oped with o-phenylenediamine substrate (Dako) and H2O2 and the
absorbance at 490 nm was measured using Cary 50 MPR
microplate reader, Varian.
Whole aggrecan (10 mg/ml) preparations extracted from fetal,
calf and adult bovine articular cartilage were coated on 96-well
Flexible PVC Microplates (BD Falcon) in 75 mM sodium
carbonate buffer (pH 9.6), O/N at 4uC. C4b deposition through
the classical pathway was determined as described above, with the
exception that the incubation with NHS was shortened to 10 min.
Direct Binding Assays
To assess the binding of C1q, FH, C4BP, C3 and properdin to
aggrecan, Maxisorp plates were coated with 5 mg/ml LCt,
V2303M LCt, D2267N LCt, Lt and Ct and appropriate positive
controls; aggregated IgG (5 mg/ml, C1q-binding), recombinant
bovine fibromodulin (2.5 mg/ml, FH- or C4BP-binding), proper-
din (5 mg/ml, C3-binding) or C3 (10 mg/ml, properdin-binding) in
75 mM sodium carbonate buffer (pH 9.6), O/N at 4uC. Negative
control was 1% BSA in PBS. Wells were blocked with 1% BSA for
2 h at RT. C1q, FH, C4BP, C3 and properdin or hi-NHS were
diluted in binding buffer (50 mM Hepes pH 7.4, 150 mM NaCl,
2 mM CaCl2, 50 mg/ml BSA) and added to wells at increasing
concentrations. Binding of properdin was also assessed from NHS,
NHS supplemented with 10 mM EDTA to block complement
activation and FB-depleted serum. After incubation for 1 h at
37uC (C1q) or at RT (FH, C4BP, properdin) or O/N at RT (C3),
bound proteins were detected with specific antibodies against C1q,
FH (A312, Quidel), C4BP (PK9008, in house), C3b and properdin
(A239, Complement Technology), followed by HRP-conjugated
secondary antibodies (Dako).
To determine the effect of ionic strength, Ca2+ and other
divalent ions on C1q and FH binding to aggrecan constructs,
plates were coated and blocked as previously. Purified C1q
(12 mg/ml) and FH (50 mg/ml) were diluted in binding buffer
supplemented with increasing concentrations of NaCl (150–
600 mM) or in 50 mM Hepes pH 7.4, 150 mM NaCl, 5 mM
EDTA, 50 mg/ml BSA. Binding of C1q and FH was detected after
1 h incubation at 37uC or at RT, respectively, as previously
described.
Electron Microscopy
The localization of C1q molecules bound to aggrecan was
analyzed by negative staining and transmission electron micros-
copy as described previously [34]. C1q was mixed with intact, fully
glycosylated bovine nasal cartilage aggrecan and the anti-
aggrecan-gold conjugates and incubated for 30 min at 4uC. Five
microliter aliquots containing 10 nM protein were adsorbed onto
carbon-coated grids for 1 min, washed with two drops of water,
and stained with two drops of 0.75% uranyl formate. The grids
were rendered hydrophilic by glow discharge at low pressure in
air. Electron microscopy was done at the Core Facility for
Integrated Microscopy (CFIM), University of Copenhagen, with a
CM 100 BioTWIN electron microscope operated at 80 kV
accelerating tension. Images were acquired with an OSIS Veleta
digital camera.
Figure 4. C1q binds the G3 domain and a part of the aggrecan core protein. A–E, using electron microscopy, complexes between bovine
nasal cartilage aggrecan and C1q were visualized by negative staining. G1 and G3 domains of aggrecan were labelled with antibody-conjugated
colloidal gold (10 nm and 5 nm, respectively) and are pointed out by black (G1) and white (G3) arrowheads. Scale bar shows 100 nm (A) and 50 nm
(B). A, several aggrecan molecules bound to the heads of C1q through their G3 domains. C1q also bound the core of aggrecan. B–D, selected
complexes between single molecules of C1q and one to three aggrecan molecules through their G3 domains, at a higher magnification. E, single
molecule of C1q bound to the core of aggrecan. F, microtiter plates were coated with aggregated IgG (positive control), adult, calf and fetal bovine
articular cartilage aggrecan and BSA (negative control) and deposited C4b from increasing concentrations of NHS was detected. The graph show the
mean and SD of three independent experiments. Statistical significance of differences was calculated using two-way ANOVA with Bonferroni posttest.
(*p,0.05, **p,0.01, ***p,0.001.).
doi:10.1371/journal.pone.0061407.g004
Aggrecan Activates Complement
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Results
Aggrecan G3 Domain Activates Classical but not Lectin
Pathway
The purity of the G3 domain constructs used in this study
(Fig. 1B) was verified by electrophoresis on a 15% Tricine gel. We
then assessed the ability of fragments of aggrecan G3 domain to
activate complement by coating proteins onto microtiter plate
wells followed by incubation with increasing concentrations of
NHS and detection of deposited complement proteins with specific
antibodies. C-type lectin-containing fragments (LCt and Lt)
induced strong deposition of C4b and C3b to a similar extent as
for positive control IgG (Fig. 2B and C), whereas the Ct fragment
lacking the lectin domain did not. Moreover, C1 was deposited
strongly on Lt and to a lower degree also on LCt, which indicates
complement activation through the classical pathway (Fig. 2A).
Less of the MAC component C9 was detected on LCt and Lt
compared to IgG but this deposition was still significantly higher
than background observed for BSA (Fig. 2D). Similarly, less
deposited C5 was detected on LCt and Lt compared to IgG (not
shown).
Further, none of the lectin pathway activators such as MBL,
ficolin 2 or ficolin 3 were deposited on the G3 fragments,
demonstrating the absence of lectin pathway activation (not
shown). We also assessed deposition of C4b from C1q-depleted
serum, in order to confirm that classical but not lectin pathway is
responsible for the observed activation in Fig. 2 B–C. The
deposition of C4b on IgG, LCt and Lt fragments was abrogated
using C1q-depleted serum, while deposition on mannan (positive
control for lectin pathway) was maintained (Fig. 3A). Similar was
observed when testing deposition of C3b (not shown).
Lectin-containing G3 Fragments Bind C1q
Using a microtiter-based assay, purified C1q was shown to bind
LCt and Lt fragments as well as IgG (Fig. 3B). The binding of C1q
to LCt/Lt fragments was dependent on ionic interactions, and was
completely disrupted by 300 mM NaCl (Fig. 3C). The presence of
EDTA that chelates calcium ions, did not affect the interaction
between C1q and LCt/Lt fragments (Fig. 3D), while the binding
of C1q to IgG was slightly affected. Further, an additional
recombinant aggrecan G3 variant, corresponding to the longest
splice form, encompassing the LCt construct with two additional
N-terminal EGF domains [17], was confirmed to bind C1q to the
same extent as LCt (not shown). This indicates that the C1q
binding site is still available even when the EGF domains are
present.
C1q Binds to the Aggrecan G3 Domain and to Additional
Sites on the Aggrecan Core Protein
To further verify the G3 domain as the C1q binding site, we
used electron microscopy to study the complexes between gold-
labelled full-length aggrecan and C1q. The head regions of C1q
appear to bind most frequently (79%) to the G3 domains pointed
out by antibodies conjugated with 5 nm colloidal gold (Fig. 4A–D).
Figure 5. The mutation D2267N within the G3 domain
decreases the complement activation capacity. A–B, microtiter
plates were coated with aggregated IgG (positive control for classical
pathway), LCt carrying the mutation D2267N or V2303M, wt LCt, and
BSA (negative control). A, increasing concentrations of NHS were added
and complement activation was measured by detecting deposited C4b.
B, plates were incubated with purified C1q, which was then detected
with specific antibodies. C, Microtiter plates were coated with untreated
or N-glycosidase F-treated D2267N LCt, aggregated IgG and BSA.
Proteins were incubated with increasing concentrations of NHS and
deposited C4b was detected. Note that in addition to deglycosylation,
the deamidation resulting from N-glycosidase F treatment reverts the
protein sequence to wild type. D, D2267N LCt was deglycosylated with
N-glycosidase F and untreated and deglycosylated proteins were
separated by SDS/PAGE followed by Coomassie Blue staining. The
graphs show the mean and SD of three independent experiments.
Statistical significance of differences was calculated using two-way
ANOVA with Bonferroni posttest. (*p,0.05, **p,0.01, ***p,0.001.).
doi:10.1371/journal.pone.0061407.g005
Aggrecan Activates Complement
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Interactions mediated by the heads of C1q are typical for other
complement-activating ECM proteins [6]. Interestingly, C1q
bound in 21% of cases also to the aggrecan core protein in the
KS- or CS-attachment region (Fig. 4A and E) indicating presence
of additional binding sites.
Aggrecan from Bovine Cartilage of Different Ages
Activates Complement
In order to confirm that also whole, intact aggrecan has capacity
to activate complement, aggrecan was extracted from fetal, calf or
adult bovine articular cartilage. Whole aggrecan activated the
classical pathway of complement, as shown by C4b deposition
(Fig. 4F) and there was no significant difference in activation with
age of animal from which aggrecan was isolated.
Figure 6. Lectin domain of aggrecan G3 module triggers limited activation of the alternative pathway. Zymosan (positive control for
alternative pathway), LCt, Lt, Ct and BSA (negative control) were coated onto microtiter plates and increasing concentrations of NHS or factor B-
depleted (FB-depl) human serum in Mg++EGTA were added. Activation of the alternative pathway was measured by detecting deposited C3b (A) and
C9 (B). Properdin (positive control for binding of C3), LCt, Lt, Ct and BSA (negative control) were coated onto microtiter plates and incubated with
purified C3, which was then detected with specific antibodies (C). The graphs show the mean and SD of three independent experiments.
doi:10.1371/journal.pone.0061407.g006
Aggrecan Activates Complement
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A Disease-associated Mutation in the C-type Lectin
Domain within the G3 Domain Decreases the
Complement Activation Capacity
We further evaluated whether two different disease-associated
mutations positioned in the G3 domain would affect the
complement activating properties. The mutations V2303M and
D2267N are associated with osteochondritis dissecans and
spondyloepimetaphyseal dysplasia, respectively. The LCt con-
struct containing the V2303M mutation maintained its capacity to
activate complement through the classical pathway, while the
D2267N mutant lost some of its capacity compared to wild type
(Fig. 5A). The binding of C1q to the D2267N mutant was also
decreased in comparison to wild type (Fig. 5B). The D2267 residue
coordinates one of the calcium residues needed to stabilize the
loops forming the binding surface of the ECM ligands [35].
However, since the complement factor interactions occur in the
presence of EDTA, it appears likely that effect of the D2267N
mutation is related to the novel N-linked glycosylation site formed.
Alternatively, the overall fold of the CLD could be disturbed by
the mutation. To exclude gross misfolding, we treated D2267N
LCt with N-glycosidase F, which resulted in an increased capacity
of the protein to activate complement compared to untreated
mutant protein (Fig. 5C) and removal of the glycosylation (Fig. 5D).
However, since N-deglycosylation with this enzyme results in the
replacement of the glycan-carrying asparagine residue with
aspartate (i.e. in this case a reversion to wild-type sequence), we
cannot conclusively say that the glycosylation per se causes the
decreased complement activation.
Aggrecan G3 Domain Weakly Activates Initial Stages of
the Alternative Pathway
To evaluate if aggrecan G3 domain can also activate the
alternative pathway, microtiter plates were coated with LCt, Lt
and Ct fragments as well as zymosan (positive control for
alternative pathway) and BSA (negative control). Then, C3b and
C9 deposited from NHS or FB-depleted serum diluted in
Mg++EGTA, were detected with specific antibodies. Using NHS,
C3b (Fig. 6A) but not C9 (Fig. 6B) was found deposited on LCt
and Lt domains while zymosan triggered deposition of both
complement factors. The C3b deposition was abrogated when
using FB-depleted serum (Fig. 6A), which confirms alternative
pathway activation by the lectin-containing fragments.
In order to find out how LCt and Lt fragments activate the
alternative pathway we investigated if properdin, which can trigger
the formation of alternative pathway C3-convertase, would bind to
these constructs. However, we only detected binding of purified
properdin but not properdin from NHS or secreted from
neutrophils (not shown). Thus, the detected interaction with
purified protein that has propensity to aggregate [36] could be an
artifact not occurring in vivo in the presence of all serum proteins.
Since the interaction between G3 fragments and properdin
could not be shown convincingly, we tested if any of the other
proteins of the alternative pathway could bind the G3 fragments
and thereby promote activation. C3 interacted with LCt and Lt to
the same extent as to the positive control properdin (Fig. 6C).
However, C3 also bound Ct to some extent, in contrast to that Ct
could not induce C3b deposition (Fig. 6A). The position of C3
upon binding the different G3 fragments might differ, which could
influence how easily C3 is cleaved and activated. We could not
detect interactions with FB or factor D (data not shown).
Figure 7. Lectin domain of aggrecan G3 module binds factor H
(FH). Microtiter plates were coated with fibromodulin (positive control
for binding of FH), LCt, Lt, Ct and BSA (negative control) and the
binding of FH from heat-inactivated NHS (hi-NHS) (A) or solution
containing purified FH (B) was detected using specific antibodies.
Fibromodulin, LCt, Lt, Ct and BSA were coated onto microtiter plates
and incubated with purified FH in a buffer supplemented with
increasing NaCl concentrations (C) or EDTA (D). In A, C and D
absorbance was normalized relative to the highest absorbance value
obtained with fibromodulin in each figure. The graphs show the mean
and SD of three independent experiments. The differences in binding
using different EDTA concentrations (D) were not statistically signifi-
cant, calculated using two-way ANOVA with Bonferroni posttest. (*,
p,0.05, **, p,0.01, ***, p,0.001.).
doi:10.1371/journal.pone.0061407.g007
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Aggrecan G3 Domain Binds Complement Inhibitor FH
Since there was less C9 deposition than C3b and C4b on LCt
and Lt fragments relative to positive control (IgG) both in the
classical but mainly alternative pathway activation, we hypothe-
sized that this could be due to binding of complement inhibitors
FH and C4BP as previously observed for fibromodulin [6,37]. We
found that FH bound LCt, Lt and Ct, both from hi-NHS (Fig. 7A)
and when purified protein was used (Fig. 7B). This indicates a
direct interaction between FH and the lectin domain, which is not
mediated by deposited C3b. The binding was only partly
dependent on ionic interactions, since it was not completely
disrupted even in the presence of 600 mM NaCl (Fig. 7C). The
interaction was not calcium dependent, as it was not affected by
the addition of the chelator EDTA (Fig. 7D). Furthermore, C4BP
did not bind G3 domain fragments (not shown). We further
investigated the binding sites of FH and C1q to LCt using a
competition assay. A mixture of FH in molar excess and C1q was
added to coated LCt and the binding of C1q was unaffected by the
presence of FH (not shown). Furthermore, C1q in molar excess did
not disrupt the binding of FH to LCt either (not shown). This
indicates that C1q and FH bind to separate sites on the LCt
construct, which has been shown for other endogenous ligands
such as fibromodulin [9]. This would allow for simultaneous
activation and regulation of complement.
Discussion
A well functioning complement system is important for
protection against foreign substances as well as altered self.
Imbalance between complement activation and regulation con-
tributes to inflammatory diseases such as RA but also to
inflammation in other joint disease, such as OA, particularly at
early stages of the disease [26]. In RA, complement can be
triggered by immune complexes, apoptotic/necrotic cells and
released cartilage proteins and it can further activate parts of both
the innate and adaptive immune system. Increasing numbers of
inhibitors of complement are being developed for possible use in
RA, showing good efficacy in the available animal models of the
disease [38,39]. The first complement inhibitor approved for
clinical use, Eculizumab, suppresses complement systemically by
inhibiting the cleavage of C5. As a consequence, patients have
increased susceptibility for certain infections. It would be more
favorable to develop more specific substance acting locally in the
joints to limit complement activation. To achieve that, it is vital to
increase the understanding of the mechanisms behind cartilage
breakdown and complement involvement within the joints. At
present, several proteins of cartilage are known to promote
inflammation by activating complement. Little is known about the
role of aggrecan in the process of complement activation, although
generation of MAC in serum incubated with bovine full-length
aggrecan was recently reported [26]. In the current study we
confirmed that human as well as bovine aggrecan activate
complement. More specifically, the ability to activate complement,
both via classical and alternative pathway, resides in the CLD of
G3 domain of aggrecan (Fig. 8). Interaction site mapping by EM
also showed that C1q can bind to central parts of the aggrecan
core protein, but we have no data showing whether this particular
interaction leads to complement activation. This appears likely
since the interaction between both G3 domain and the central
core part of aggrecan appear to be mediated by the globular heads
of C1q rather than collagenous stalk domains. Such binding to the
globular head is typical for known activators of the classical
pathway such as IgG and ECM proteins fibromodulin and
osteoadherin [6,9]. Accordingly, interactions of biglycan, decorin
and COMP are localized to stalk regions of C1q, which leads to
inhibition of the classical pathway presumably due to competition
of these ligands with C1r and C1s or steric hindrance preventing
the access of ligands (C4 and C2) [5].
Based on the present data one may speculate about the exact
binding site for C1q on CLD of G3. CLD binds its ECM ligands
in a strictly calcium-dependent manner to the calcium-stabilized
loops. Since the binding of C1q to CLD occurs in the presence of
EDTA, it indicates separate binding sites of these proteins on
CLD. Further, the presence of the EGF or CCP domains in G3
did not affect the C1q binding, which further restricts the possible
C1q binding sites on CLD. Nevertheless, the studies of G3
fragments carrying disease-associated missense mutations in the
CLD, provide us with additional information about the binding
site of C1q. Since the D2267N mutation in CLD partially
disturbed the C1q interaction, we suggest that the C1q binding site
is in proximity of the mutant amino acid residue, which carries an
N-linked carbohydrate probably forming a steric hindrance for
C1q-binding. Interestingly, D2267N is associated with spondyloe-
pimetaphyseal dysplasia [22]. However, further efforts will be
needed to establish if and how complement may be involved in this
disease.
It is plausible that the observed binding of FH to G3 domain is
responsible for relatively lower generation of MAC in comparison
to activation and deposition of C4b (Fig. 8). We propose that the
binding of FH to aggrecan results in inhibition of the alternative
pathway C3 and C5 convertases, which in turn yields appreciable
decrease in generation of MAC, particularly apparent for the
Figure 8. Schematic representation of interactions between aggrecan G3 domain and complement. C1-complex binds the aggrecan G3
domain via the globular heads of C1q, which leads to activation of the classical pathway and the deposition of C4b. Classical pathway C3-convertase
is formed, which generates C3b, which is further enhanced by the alternative pathway acting as amplification loop. Furthermore, interaction of G3
with C3 leads to low degree activation of the alternative pathway. Deposited C3b is included in C3- and C5 convertases that finally lead to the
formation of MAC. Complement factor FH also binds G3 and is suggested to attenuate the amount of deposited C3b and formed MAC.
doi:10.1371/journal.pone.0061407.g008
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alternative pathway. FH is able to affect later stages of the classical
pathway as well, since the alternative pathway, which it controls,
acts as amplification loop to the classical pathway. The simulta-
neous interactions of ligands with C1q and complement inhibitors
FH and C4BP are frequently observed for endogenous ligands, for
example fibromodulin [6], osteoadherin [6], C-reactive protein
[40], amyloid [41], prions [42], DNA [40] and dying cells [43].
This contrasts to the interaction between C1q and immune
complexes, in which case no inhibitors bind, resulting in full
complement activation. The binding of complement inhibitors to
endogenous ligands also interacting with C1q does not completely
block complement activation but enables certain level of opsonisa-
tion with C3b and its fragments while preventing massive
complement activation and assembly of the terminal MAC
pathway and release of C5a, which could both trigger significant
inflammation. Interestingly, FH interacts not only with CLD but
also the construct containing only CCP domain and tail extension.
This together with observations that C1q and FH can not compete
out each other from binding to the G3 domain and that these two
interactions differ in sensitivity to ionic strength, indicate that the
binding sites for C1q and FH on G3 are not likely to overlap.
In cartilage, there is a physiological tissue turnover of
components with resulting release of protein fragments, including
aggrecan, also under normal conditions. In such situation,
complement may have an important role in promoting clearance
of these fragments to maintain a normal, non-immune stimulatory
environment. However, at the time of heavily increased fragment
release during RA or OA, excessive complement activation and
inadequate regulation could cause a hazardous inflammatory state
[44]. What initially disturbs the balance between complement
activation and regulation is not clear, but both the availability and
concentration of complement triggers in the joint could be crucial
factors affecting the detrimental switch in the sensitive balance. It
is plausible that aggrecan fragments contribute to the inflamma-
tion of the RA or OA joint when released or made more accessible
to complement in the partially degraded cartilage. However, this
process is most likely not an initial trigger of the disease but acts
more as an amplification of the initial activation of the immune
system leading to increased proteolytic activity. The nature and
amount of released fragments of aggrecan during pathological
degradation, could affect their capacity to activate complement
and to bind FH.
Aberrant and misguided complement activation is the culprit in
many acute and chronic diseases including common joint diseases.
In both RA and OA, articular cartilage is destroyed and during
this process there is widespread release of cartilage constituents
including fragments of aggrecan. We showed that this, in turn,
leads to activation of complement providing further rationale for
clinical testing in joint diseases of complement inhibitors currently
under development.
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